Answers are grounded in this paper and cite their sources.
This analysis highlights challenges in companion diagnostic tests for lung cancer, suggesting improvements for predictive biomarkers like ALK and PD-L1.
Introduction Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains the leading cause of cancer-related mortality worldwide. Accurate assessment of predictive biomarkers, such as ALK and PD-L1, is essential for personalized therapy and to guide clinical decisions. Companion diagnostic (CDx) tests play a crucial role in this context.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: